⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18233622 | 0.86 | NCF1 (0.38) | — | |
| SCHEMBL25924151 | 0.80 | GBA1 (0.33) | — | |
| SCHEMBL23696790 | 0.79 | — | — | |
| SCHEMBL17250047 | 0.79 | NCF1 (0.43) | — | |
| SCHEMBL24832948 | 0.78 | — | — | |
| SCHEMBL23695860 | 0.78 | PIK3CD (0.41) | — | |
| SCHEMBL19782061 | 0.77 | HTR2C (0.32) | — | |
| SCHEMBL8396257 | 0.77 | — | — | |
| SCHEMBL24942654 | 0.75 | NCF1 (0.39) | — | |
| SCHEMBL20666382 | 0.75 | MEN1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |